tinzaparin
Trade name: Innohep
Small moleculeapproved
Approved
Jul 14, 2000
Tinzaparin is an antithrombotic drug in the heparin group. It is a low molecular weight heparin (LMWH) marketed as Innohep worldwide. It has been approved by the U.S. Food and Drug Administration (FDA) for once daily treatment and prophylaxis of deep vein thrombosis (DVT) and pulmonary embolism (PE). — Wikipedia
Clinical trial activity
41 trials · 51 clinical orgs · 2 marketing orgs
Phase 1
1
Phase 2
18
Phase 3
13
Phase 4
16
Earliest trial started Oct 1, 1993 (NCT00628576)
Timeline
1990s
- Jan 1, 1993
Earliest Phase 3 Sponsor(trial)
2000s
- Jul 14, 2000
Earliest FDA Approval
- Jul 14, 2000
Leo Pharma — NDA Secondary Org
- Jan 1, 2002
Earliest Phase 2 Sponsor(trial)
- Jan 1, 2005
Earliest Phase 1 Sponsor(trial)
Indications
Approved for
Studied for
- Acute Chest Syndrome · Phase 3
- Acute Kidney Injury · Phase 4
- Adenocarcinoma · Phase 3
- Anemia · Phase 3
- Anemia, Sickle Cell · Phase 3
- Anticoagulants · Phase 4
- Carcinoma, Non-Small-Cell Lung · Phase 3
- Carcinoma, Ovarian Epithelial · Phase 2
- Colorectal Neoplasms · Phase 3
- COVID-19 · Phase 3
- Diabetes Mellitus · Phase 4
- Fetal Growth Retardation · Phase 4
- General Surgery · Phase 4
- Hemorrhage · Phase 4
- Heparin, Low-Molecular-Weight · Phase 3
- Ischemic Stroke · Phase 2
- Kidney Failure, Chronic · Phase 4
- Kidney Neoplasms · Phase 1/Phase 2
- Leg Injuries · Phase 3
- Liver Neoplasms · Phase 4
- Lung Neoplasms · Phase 3
- Lymphoma · Phase 2
- Multiple Myeloma · Phase 2
- Neoplasms · Phase 2
- Pancreatic Neoplasms · Phase 4
- Postthrombotic Syndrome · Phase 4
- Pulmonary Embolism · Phase 4
- Renal Dialysis · Phase 4
- Renal Replacement Therapy · Phase 4
- Therapeutics · Phase 4
- Thrombocytopenia · Phase 4
- Thromboembolism · Phase 4
- Thrombosis · Phase 4
- Venous Thromboembolism · Phase 4
Mechanism of action
- Antithrombin-IIIACTIVATOR
SERPINC1 activator
Inhibits coagulation by activating antithrombin III; ATIII then binds to F10; It's a low-molecular-weight heparin
Approval history
- approvedJul 14, 2000
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Delivery
- Parenteral
- Availability
- Discontinued
Oral
No
Parenteral
Yes
Topical
No
Black box warning
Sources
- WikipediaTinzaparin sodium ↗
- NCATS7UQ7X4Y489 ↗
- ChEMBLCHEMBL6068592 ↗
- ChEMBLCHEMBL1201414 ↗
Also known as
- innohep
- innohep
- innohep
- innohep
- logiparin
- logiparin
- tinzaparin
- tinzaparin
- tinzaparin
- tinzaparin
- tinzaparin
- tinzaparin
- tinzaparin sodium
- tinzaparin sodium
- tinzaparin sodium
- tinzaparin sodium
- tinzaparin sodium
- tinzaparin sodium
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06370273 | Phase 3 | Nov 12, 2024 | University of London |
| NCT06020560 | Phase 4 | Mar 23, 2023 | University of Copenhagen |
| NCT05625932 | Phase 3 | Dec 31, 2022 | Galician Research Group on Digestive Tumors, Hospital General Universitario Gregorio Marañon, Leo Pharma |
| NCT05255003 | Phase 4 | Aug 29, 2022 | University of Ottawa |
| NCT05245877 | Phase 4 | Aug 17, 2022 | University of Helsinki |
| NCT05284552 | Phase 2 | Jul 12, 2022 | Government of Sweden, Linkoping University, Västervik Hospital |
| NCT05178628 | Phase 3 | Feb 10, 2022 | — |
| NCT04794569 | Phase 4 | Nov 15, 2021 | Leo Pharma, The Jewish General Hospital, Montreal QC, Canada, University of Toronto |
| NCT04808882 | Phase 2 | Apr 14, 2021 | Assistance Publique - Hôpitaux de Paris |
| NCT04731558 | Phase 4 | Feb 10, 2021 | Government of Finland, The Finnish Medical Association, University of Helsinki |
| NCT04741464 | N/A | Feb 2, 2021 | University of Picardie Jules Verne |
| NCT04730856 | Phase 3 | Feb 1, 2021 | Hospital Universitario Infanta Leonor |
| NCT04344756 | Phase 2 | Apr 20, 2020 | Assistance Publique - Hôpitaux de Paris |
| NCT03614741 | Phase 4 | Oct 1, 2018 | University of Tampere |
| NCT03240120 | Phase 3 | Sep 1, 2017 | The University of Hong Kong |
| NCT03090880 | Phase 3 | Apr 1, 2017 | Government of France, National Cancer Institute, France, University of Paris |
| NCT02580773 | Phase 3 | Nov 1, 2015 | Leo Pharma, University of Paris |
| NCT02260414 | Phase 2 | Apr 14, 2015 | Leo Pharma, University of Lyon |
| NCT01930396 | Phase 4 | Sep 1, 2013 | Leo Pharma, McMaster University, University of Western Ontario |
| NCT01828697 | Phase 4 | Apr 1, 2013 | Aspen Pharmaceuticals, Netherlands Organisation for Scientific Research, University of Amsterdam, University of Lyon |
Showing 20 of 41 trials
Page 1 / 3
Organizations
Research & Development (51)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Leo Pharma | For profit | 18 | 2 | 4 | 1994 |
| University of Ottawa | Academic/Hospital | 5 | 5 | 3 | 2002 |
| University of Calgary | Academic/Hospital | 3 | 3 | 1 | 1994 |
| University of Paris | Academic/Hospital | 3 | 3 | 1 | 2007 |
| Assistance Publique - Hôpitaux de Paris | Academic/Hospital | 2 | 2 | 1 | 2020 |
| Canadian Institutes of Health Research (CIHR) | Academic/Hospital | 2 | 0 | 1 | 1994 |
| Celgene | For profit | 2 | 0 | 2 | 2004 |
| DuPont | For profit | 2 | 0 | 1 | 1994 |
| McMaster University | Academic/Hospital | 2 | 1 | 2 | 2005 |
| University of Helsinki | Academic/Hospital | 2 | 2 | 1 | 2021 |
| University of Lyon | Academic/Hospital | 2 | 1 | 2 | 2013 |
| University of Western Ontario | Academic/Hospital | 2 | 1 | 2 | 2005 |
| Aalborg University | Academic/Hospital | 1 | 1 | 1 | 1993 |
| Aarhus University | Academic/Hospital | 1 | 1 | 1 | 2011 |
| Anemia Working Group Romania | Academic/Hospital | 1 | 1 | 1 | 2009 |
| Aspen Pharmaceuticals | For profit | 1 | 0 | 1 | 2013 |
| Carol Davila University of Medicine and Pharmacy | Academic/Hospital | 1 | 0 | 1 | 2009 |
| Coloplast A/S | For profit | 1 | 0 | 1 | 2004 |
| Complejo Hospitalario Xeral Calde | Academic/Hospital | 1 | 1 | 1 | 2005 |
| Duke University | Academic/Hospital | 1 | 1 | 1 | 2004 |
51 organizations
Page 1 / 3
Marketing (2)
| Organization | Org type | Relationship | Date |
|---|---|---|---|
| DuPont | For profit | NDA | — |
| Leo Pharma | For profit | NDA2 | Jul 14, 2000 |